Osmotica Pharmaceutical   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Marietta GA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2007
NCT00558337
First Marketed Drug
2005
nifedipine (procardia)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

OSMOTICA | OSMOTICA PHARM | Osmotica Pharmaceutical Argentina S.A. | Osmotica Pharmaceutical US LLC | Osmotica Pharmaceutical, VP - Global Clinical Development and Medical Affairs | OSMOTICA PHARM CORP | OSMOTICA PHARM US | RevitaLid Inc. | RVL PHARMA INC | RVL PHARMS

Active Ingredients

Marketed Drugs (11)

amantadine (symmetrel) (2018)

desvenlafaxine (pristiq) (2013)

donepezil (aricept) (2016)

hydromorphone (diladid) (2016)

icosapent ethyl (vascepa) (2014)

methylphenidate (ritalin) (2017)

nifedipine (procardia) (2005)

omega-3 fatty acids (omacor) (2014)

oxybutynin (ditropan) (2009)

oxymetazoline (ocuclear) (2020)

venlafaxine (effexor) (2008)

Drugs in Phase 3 Trials (4)

amantadine (symmetrel) (2 trials)

arbaclofen (5 trials)

baclofen (lioresal) (1 trial)

rvl-1201 (4 trials)

Drugs in Phase 2 Trials (2)

carbidopa (sinemet) (1 trial)

levodopa (larodopa) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Osmotica Pharmaceutical (0) Acquired (1)

revacept (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharoptosis (Phase 3)

Dyskinesias (Phase 3)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 3)

Parkinson Disease (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 7